Deep Track Capital LP Invests $15.32 Million in Immunocore Holdings plc (NASDAQ:IMCR)

Deep Track Capital LP bought a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 519,376 shares of the company's stock, valued at approximately $15,322,000. Deep Track Capital LP owned 1.04% of Immunocore at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of IMCR. Groupama Asset Managment bought a new stake in shares of Immunocore in the fourth quarter worth $17,700,000. T. Rowe Price Investment Management Inc. raised its stake in shares of Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock worth $197,657,000 after purchasing an additional 200,373 shares in the last quarter. Primecap Management Co. CA boosted its holdings in shares of Immunocore by 8.0% in the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock valued at $78,722,000 after buying an additional 196,530 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Immunocore in the 4th quarter valued at approximately $5,697,000. Finally, Principal Financial Group Inc. grew its stake in shares of Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock valued at $17,007,000 after buying an additional 109,206 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. The trade was a 60.40% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 10.40% of the stock is owned by corporate insiders.

Immunocore Stock Performance

Shares of NASDAQ:IMCR traded up $0.87 during midday trading on Monday, reaching $29.27. The company had a trading volume of 137,738 shares, compared to its average volume of 429,399. The company's 50 day moving average price is $28.81 and its 200 day moving average price is $30.14. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 52-week low of $23.15 and a 52-week high of $59.82. The stock has a market cap of $1.47 billion, a P/E ratio of -30.83 and a beta of 0.75.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. The business had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. Immunocore's revenue was up 33.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.49) EPS. As a group, sell-side analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IMCR has been the subject of several recent analyst reports. Oppenheimer raised their target price on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. Needham & Company LLC reissued a "buy" rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday, April 10th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. Finally, Mizuho reduced their price target on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $58.13.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.